MCID: ESP025
MIFTS: 41

Esophagus Adenocarcinoma malady

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Esophagus Adenocarcinoma

Aliases & Descriptions for Esophagus Adenocarcinoma:

Name: Esophagus Adenocarcinoma 12 14
Adenocarcinoma of Esophagus 12 42 69
Oesophageal Adenocarcinoma Nos 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4914
MeSH 42 C562730
NCIt 47 C4025
SNOMED-CT 64 276803003
UMLS 69 C0279628

Summaries for Esophagus Adenocarcinoma

Disease Ontology : 12 An esophageal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Esophagus Adenocarcinoma, also known as adenocarcinoma of esophagus, is related to barrett esophagus/esophageal adenocarcinoma and bile duct clear cell adenocarcinoma, and has symptoms including chest pain, nausea and vomiting and obesity. An important gene associated with Esophagus Adenocarcinoma is ATP4A (ATPase H+/K+ Transporting Alpha Subunit), and among its related pathways/superpathways are Pathways in cancer and MicroRNAs in cancer. The drugs Menthol and Capecitabine have been mentioned in the context of this disorder. Related phenotypes are digestive/alimentary and endocrine/exocrine gland

Related Diseases for Esophagus Adenocarcinoma

Diseases related to Esophagus Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 100)
id Related Disease Score Top Affiliating Genes
1 barrett esophagus/esophageal adenocarcinoma 11.0
2 bile duct clear cell adenocarcinoma 10.3 PTGS2 TP53
3 cystinosis, nephropathic 10.3 ERBB2 TP53
4 lung clear cell-sugar-tumor 10.3 ERBB2 TP53
5 clear cell adenofibroma 10.3 CDKN2A TP53
6 lacrimal gland adenoid cystic carcinoma 10.3 CDKN2A TP53
7 pericardium leiomyoma 10.3 CDKN2A TP53
8 skeletal tuberculosis 10.2 CDKN2A ERBB2
9 small intestinal l-cell glucagon-like peptide producing tumor 10.2 ATP4A PTGS2
10 adult central nervous system mature teratoma 10.2 ERBB2 TP53
11 spondylarthropathy 10.2 CDKN2A TP53
12 malignant mediastinal neurogenic neoplasm 10.2 TP53 WWOX
13 lacrimal gland squamous cell carcinoma 10.2 CDKN2A TP53
14 posterior myocardial infarction 10.2 CDKN2A ERBB2
15 ideomotor apraxia 10.2 CDX2 PTGS2 TP53
16 reactive arthritis 10.2 ERBB2 PTGS2 TP53
17 brachydactyly tibial hypoplasia 10.2 CDKN2A PTGS2
18 hyperornithinemia-hyperammonemia-homocitrullinemia syndrome 10.2 CDX2 PTGS2 TP53
19 pituitary carcinoma 10.2 CDX2 PTGS2 TP53
20 his bundle tachycardia 10.2 CDX2 ERBB2 TP53
21 oral squamous cell carcinoma 10.2 CDX2 PTGS2 TP53
22 bacterial gastritis 10.2 ATP4A CDX2 PTGS2
23 odontotrichoungual-digital-palmar syndrome 10.2 CDX2 ERBB2 PTGS2
24 urethral verrucous carcinoma 10.2 CDKN2A PTGS2 TP53
25 dysembryoplastic neuroepithelial tumor 10.2 ERBB2 PTGS2 TP53
26 postpoliomyelitis syndrome 10.2 CDKN2A CDX2 TP53
27 spastic ataxia 5 10.2 CDKN2A CDX2 TP53
28 aicardi-goutieres syndrome 10.2 CDKN2A CDX2 TP53
29 mitochondrial encephalomyopathy 10.2 CDKN2A PTGS2 TP53
30 pacinian tumor 10.2 CDKN2A CDX2 TP53
31 endometrial squamous cell carcinoma 10.2 CDKN2A TP53
32 oro-mandibular-limb hypogenesis syndrome 10.2 CDKN2A ERBB2 TP53
33 allergic contact dermatitis 10.2 CDKN2A CDX2 TP53
34 alpha chain disease 10.2 CDKN2A PTGS2 TP53
35 estrogen-receptor positive breast cancer 10.2 CDKN2A ERBB2 TP53
36 ornithinemia 10.2 CDKN2A PTGS2 TP53
37 vestibular gland benign neoplasm 10.2 CDKN2A PTGS2 TP53
38 pyomyositis 10.2 CDKN2A ERBB2 TP53
39 myotonia congenita 10.2 CDKN2A CDX2 ERBB2
40 prostatic adenoma 10.1 CDKN2A ERBB2 TP53
41 solitary plasmacytoma of chest wall 10.1 CDX2 ERBB2 PTGS2
42 pearson syndrome 10.1 CDKN2A ERBB2 TP53
43 trachea squamous cell carcinoma 10.1 CDKN2A ERBB2 TP53
44 ampulla of vater neoplasm 10.1 CDKN2A TP53
45 in situ pulmonary adenocarcinoma 10.1 CDKN2A PTGS2 TP53
46 adenocarcinoma 10.1
47 functional diarrhea 10.1 ATP12A ATP4A
48 scrotum melanoma 10.1 ATP12A ATP4A
49 secondary syphilis 10.1 ATP12A ATP4A
50 brain edema 10.1 ATP12A ATP4A

Graphical network of the top 20 diseases related to Esophagus Adenocarcinoma:



Diseases related to Esophagus Adenocarcinoma

Symptoms & Phenotypes for Esophagus Adenocarcinoma

Human phenotypes related to Esophagus Adenocarcinoma:

32 (show all 10)
id Description HPO Frequency HPO Source Accession
1 chest pain 32 HP:0100749
2 nausea and vomiting 32 HP:0002017
3 obesity 32 HP:0001513
4 gastroesophageal reflux 32 HP:0002020
5 feeding difficulties in infancy 32 HP:0008872
6 cough 32 HP:0012735
7 lymphadenopathy 32 HP:0002716
8 clinodactyly of the 5th toe 32 HP:0001864
9 esophageal carcinoma 32 HP:0011459
10 barrett esophagus 32 HP:0100580

MGI Mouse Phenotypes related to Esophagus Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.92 ATP12A ATP4A CDKN2A CDX1 CDX2 ERBB2
2 endocrine/exocrine gland MP:0005379 9.86 TP53 WWOX ATP4A CDKN2A CDX1 CDX2
3 neoplasm MP:0002006 9.63 CDKN2A CDX2 ERBB2 PTGS2 TP53 WWOX
4 pigmentation MP:0001186 9.26 CDKN2A CDX1 MFRP TP53
5 skeleton MP:0005390 9.17 CDKN2A CDX1 CDX2 ERBB2 PTGS2 TP53

Drugs & Therapeutics for Esophagus Adenocarcinoma

Drugs for Esophagus Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 215)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4 2216-51-5 16666
2
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154361-50-9 60953
3
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
4
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
5
Levoleucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1 68538-85-2
6
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
7
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
8
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
10
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 58-05-9 54575, 6560146 143
11
Camptothecin Experimental Phase 4,Phase 2,Phase 1 7689-03-4
12 Liver Extracts Phase 4,Phase 2,Phase 1
13 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
14 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
15 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
16 topoisomerase I inhibitors Phase 4,Phase 3,Phase 2,Phase 1
17 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
18 Antidotes Phase 4,Phase 2,Phase 3,Phase 1
19 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
20 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
22 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
23 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1
24 Vitamin B Complex Phase 4,Phase 2,Phase 3,Phase 1
25 Vitamins Phase 4,Phase 2,Phase 3,Phase 1
26 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
27 glucocorticoids Phase 4,Phase 1,Phase 2
28 Hormone Antagonists Phase 4,Phase 1,Phase 2
29 Hormones Phase 4,Phase 1,Phase 2
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 1,Phase 2
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Antiemetics Phase 4,Phase 1,Phase 2
33 Antineoplastic Agents, Hormonal Phase 4,Phase 1,Phase 2
34 Autonomic Agents Phase 4,Phase 1,Phase 2
35 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
36 Methylprednisolone acetate Phase 4
37 Methylprednisolone Hemisuccinate Phase 4
38 Neuroprotective Agents Phase 4
39 Prednisolone acetate Phase 4
40 Prednisolone hemisuccinate Phase 4
41 Prednisolone phosphate Phase 4
42 Folate Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1
43 Vitamin B9 Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1
44
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
45
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
46
Cetuximab Approved Phase 2, Phase 3, Phase 1 205923-56-4 56842117 2333
47
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
48
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
49
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
50
Trioxsalen Approved Phase 3,Phase 2 3902-71-4 5585

Interventional clinical trials:

(show top 50) (show all 332)
id Name Status NCT ID Phase
1 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
2 Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours Completed NCT00220168 Phase 4
3 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4
4 Barretts oEsophageal Resection With Steroid Therapy Trial Recruiting NCT02004782 Phase 4
5 Combination Chemotherapy in Treating Patients With Esophageal Cancer Unknown status NCT00041262 Phase 3
6 Endoscopy Every 2 Years or Only as Needed in Monitoring Patients With Barrett Esophagus Unknown status NCT00987857 Phase 3
7 Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002883 Phase 3
8 Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002884 Phase 3
9 Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer Unknown status NCT00509561 Phase 2, Phase 3
10 Confocal Endomicroscopy for Barrett's Esophagus Completed NCT00487695 Phase 3
11 Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer Completed NCT00047112 Phase 3
12 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00002631 Phase 3
13 Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00003118 Phase 3
14 Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer Completed NCT00020787 Phase 3
15 Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy Completed NCT01243398 Phase 3
16 Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer Completed NCT00978549 Phase 3
17 Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer Completed NCT00861094 Phase 2, Phase 3
18 Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Health-Related Quality of Life in Patients Undergoing Total Gastrectomy for Adenocarcinoma Completed NCT01491698 Phase 3
19 Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus Recruiting NCT02509286 Phase 3
20 NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) Recruiting NCT01726452 Phase 3
21 Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction Recruiting NCT01523015 Phase 2, Phase 3
22 STRETTA ,Radio Frequency Ablation (RFA) v/s Sham Therapy for the Treatment of Refractory GERD Recruiting NCT02935881 Phase 3
23 Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Recruiting NCT02628665 Phase 3
24 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Recruiting NCT02564263 Phase 3
25 Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma Recruiting NCT01404156 Phase 2, Phase 3
26 Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy Recruiting NCT02551458 Phase 2, Phase 3
27 Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer Recruiting NCT00450203 Phase 2, Phase 3
28 Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma Recruiting NCT01924819 Phase 2, Phase 3
29 Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation Recruiting NCT02741856 Phase 2, Phase 3
30 Comparison Between Radiofrequency Ablation and Hypofractionated Proton Beam Radiation for Recurrent/Residual HCC Recruiting NCT01963429 Phase 3
31 Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Active, not recruiting NCT01196390 Phase 3
32 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia Active, not recruiting NCT00357682 Phase 3
33 A Randomized, Controlled, Multicenter Study to Compare Preoperative Radiochemotherapy With Preoperative Chemotherapy in Patients With Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Active, not recruiting NCT03013010 Phase 3
34 Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery Active, not recruiting NCT01107639 Phase 3
35 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer Active, not recruiting NCT00052910 Phase 3
36 Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma Unknown status NCT00964080 Phase 1, Phase 2
37 Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer Unknown status NCT01307956 Phase 2
38 C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer Unknown status NCT02344810 Phase 1, Phase 2
39 Tethered Capsule Endoscope in Screening Participants for Barrett Esophagus Unknown status NCT00903136 Phase 1, Phase 2
40 Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus Unknown status NCT00003326 Phase 2
41 Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus Unknown status NCT00005607 Phase 2
42 Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer Unknown status NCT00006472 Phase 2
43 Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery Unknown status NCT00005876 Phase 2
44 Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer Unknown status NCT00004236 Phase 2
45 Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer Unknown status NCT00865982 Phase 2
46 Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT00763646 Phase 2
47 Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH Unknown status NCT01855854 Phase 2
48 A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma Unknown status NCT00183885 Phase 2
49 A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies Unknown status NCT00057395 Phase 1, Phase 2
50 Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma Completed NCT00220103 Phase 2

Search NIH Clinical Center for Esophagus Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma of esophagus

Genetic Tests for Esophagus Adenocarcinoma

Anatomical Context for Esophagus Adenocarcinoma

Publications for Esophagus Adenocarcinoma

Articles related to Esophagus Adenocarcinoma:

id Title Authors Year
1
Epigenetic regulation on the gene expression signature in esophagus adenocarcinoma. ( 28049580 )
2016
2
In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma. ( 24708360 )
2014
3
Esophagus adenocarcinoma in a young patient with celiac disease; Is celiac disease a predisposing factor for esophagus adenocarcinoma as well as squamous cell carcinoma? ( 26185881 )
2014
4
Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis. ( 21166737 )
2010
5
Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. ( 17236199 )
2007
6
Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. ( 16985029 )
2006
7
Meningeal carcinomatosis in patient with esophagus adenocarcinoma. ( 9105327 )
1997

Variations for Esophagus Adenocarcinoma

Expression for Esophagus Adenocarcinoma

Search GEO for disease gene expression data for Esophagus Adenocarcinoma.

Pathways for Esophagus Adenocarcinoma

GO Terms for Esophagus Adenocarcinoma

Biological processes related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 anterior/posterior axis specification GO:0009948 9.32 CDX1 CDX2
2 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.26 ATP12A ATP4A
3 replicative senescence GO:0090399 9.16 CDKN2A TP53
4 regulation of somitogenesis GO:0014807 8.96 CDX1 CDX2
5 negative regulation of immature T cell proliferation in thymus GO:0033088 8.62 CDKN2A ERBB2

Molecular functions related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase activity GO:0005391 8.96 ATP12A ATP4A
2 hydrogen:potassium-exchanging ATPase activity GO:0008900 8.62 ATP12A ATP4A

Sources for Esophagus Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....